Table 5 Use of gadolinium contrast agents for CMR studies in peer reviewed publications
Contrast agent | Publications (percent) by year | |||||||
|---|---|---|---|---|---|---|---|---|
| Â | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | Total |
Gadopentetate Dimeglumine | 13 (59) | 10 (52.6) | 11 (42.3) | 15 (48.3) | 24 (60) | 25 (55.5) | 16 (32) | 114 (48.9) |
Gadodiamide | 4 (18.2) | 4 (21) | 5 (19.2) | 8 (25.8) | 4 (10) | 5 (11.1) | 9 (18) | 39 (16.7) |
Gadoterate Meglumine | 0 (0) | 0 (0) | 2 (7.7) | 4 (13) | 0 (0) | 5 (11.1) | 4 (8) | 15 (6.5) |
Gadobutrol | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (7.5) | 0 (0) | 2 (4) | 5 (2.2) |
Gadobenate Dimeglumine | 0 (0) | 0 (0) | 0 (0) | 1 (3.2) | 1 (2.5) | 1 (2.3) | 1 (2) | 4 (1.8) |
Gadoversetamide | 0 (0) | 0 (0) | 1 (3.8) | 0 (0) | 1 (2.5) | 0 (0) | 0 (0) | 2 (0.8) |
Not specified | 5 (22.8) | 5 (26.4) | 7 (27) | 3 (9.7) | 7 (17.5) | 9 (20) | 18 (36) | 54 (23.1) |
Total | 22 (100) | 19 (100) | 26 (100) | 31 (100) | 40 (100) | 45 (100) | 50 (100) | 233 (100) |